LAKSHIKA RANAWEERA: Open Payments
NPI 1285830653 · MANHATTAN, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$651 in 25 payments from 9 companies in 2025. Trend: 2023 $118 · 2024 $135 · 2025 $651
Food & beverage: $651
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $172 |
| Alkermes, Inc. | 5 | $111 |
| Janssen Pharmaceuticals, Inc | 2 | $102 |
| Otsuka America Pharmaceutical, Inc. | 4 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Lundbeck LLC | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
Products named: REXULTI, VRAYLAR, ARISTADA, SPRAVATO, TRINTELLIX, FANAPT, CAMZYOS, Venovo.
Industry payments across KS — which companies pay providers there.
